Study analysis · Alzheimer's & Dementia · 2023
Could a fecal transplant actually improve memory and thinking in dementia patients?
In a small study of 10 people with dementia and a severe gut infection, receiving a fecal transplant led to noticeable improvements in memory and thinking tests one month later.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study is like watching a few people who got a special treatment and then seemed to get better. But without comparing them to people who didn't get the treatment, we can't know if the treatment actually helped or if they just got better on their own. So we can say 'these people got better after the treatment' but we can't say 'the treatment caused them to get better.'
What’s the bottom line?
Scientists gave 10 older people with memory loss and a bad gut infection a fecal transplant (putting healthy poop into their gut). One month later, their memory and thinking tests improved a lot.
How strong is this study?
This study is like a small experiment where everyone got the same thing and no one was in a 'pretend' group. That makes it hard to trust the results because we don't know if the improvement would have happened anyway. A better study would have a comparison group and use random chance to decide who gets the treatment, so we can be more sure the treatment is what really made a difference.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
14 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a case series with no control group, no randomization, and no blinding. Therefore, it cannot establish cause-effect relationships. Any observed improvements could be due to natural history, placebo effects, or confounding factors.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information disclosed in the provided abstract.
The study appears to be conducted by academic researchers, but the full article may contain COI and funding statements not included here.
Key takeaways
- 01
Before treatment, average memory test score was 10/30; after, it was 16/30.
- 02
Another test of dementia severity improved from 10 to 5.5 (lower is better).
- 03
This is a big improvement—like going from needing a lot of help to needing less help—but the study is too small and lacks a comparison group to be sure the transplant caused it.
Surprising findings
- Cognitive improvement of 6 points on MMSE in just one month after FMTTypical dementia progression is slow decline; an improvement of this magnitude is rarely seen with existing treatments, especially in severe dementia (baseline MMSE 10).
- The bacteria linked to improvement are opposite to what's often found in Alzheimer'sAlzheimer's patients usually have more Proteobacteria and less Bacteroidetes; FMT reversed that pattern, aligning with healthier microbiota.
Practical takeaways
Focus on gut health through diet, probiotics, and avoiding unnecessary antibiotics to maintain a diverse microbiome.
This study does not prove that improving gut health alone will prevent or treat dementia; correlation is not causation.
low confidenceIf a loved one with dementia gets a severe C. diff infection, treating it promptly is critical – and may have added cognitive benefits.
FMT is currently only approved for recurrent C. diff; off-label use for dementia is not recommended outside clinical trials.
low confidenceConsider joining clinical trials exploring FMT or microbiome interventions for cognitive decline.
Many trials are ongoing; check ClinicalTrials.gov for opportunities.
medium confidenceWhy this study matters
The Gut-Brain Connection Gets Real
After fecal microbiota transplantation (FMT) for severe C. diff infection, dementia patients showed a median MMSE score increase from 10 to 16 (out of 30) and a median CDR-SB decrease from 10 to 5.5 (lower is better) one month post-treatment.
This suggests that changing the gut microbiome might directly influence brain function, offering a potential new avenue for dementia treatment.
From Bug to Brain: The Microbiome Shift
Before FMT, patients had high levels of Proteobacteria (often linked to inflammation); after, Bacteroidetes increased. These shifts correlated with cognitive improvement.
It points to specific bacterial groups that might be beneficial or harmful for brain health, which could lead to targeted probiotics.
Big Improvements, But Huge Caveats
The study had no control group, only 10 patients, and follow-up was just 1 month. Patients were also receiving standard CDI treatment, so improvement could be due to treating the infection, not FMT itself.
It highlights the excitement and danger of early-stage research: promising results that need rigorous confirmation.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 10 older people with memory loss and a bad gut infection a fecal transplant (putting healthy poop into their gut). One month later, their memory and thinking tests improved a lot.
Research results
Before treatment, average memory test score was 10/30; after, it was 16/30. Another test of dementia severity improved from 10 to 5.5 (lower is better).
What this means - more context
This is a big improvement—like going from needing a lot of help to needing less help—but the study is too small and lacks a comparison group to be sure the transplant caused it.
To evaluate whether fecal microbiota transplantation (FMT) can improve cognition in patients with dementia and Clostridioides difficile infection (CDI).
In a case series of 10 dementia patients with severe CDI, FMT was associated with improved cognitive function (MMSE increased from median 10 to 16; CDR-SB decreased from median 10 to 5.5) and shifts in gut microbiota (increased Bacteroidetes, decreased Proteobacteria) one month post-treatment.
Methods Used
10 patients (63-90 years, 80% female) with dementia and severe CDI underwent FMT; cognitive tests (MMSE, CDR-SB) were performed one month before and after FMT; stool samples analyzed by PCR before and 3 weeks after FMT.
Main Finding
FMT in dementia patients with CDI led to significant cognitive improvement (median MMSE +6 points, median CDR-SB -4.5 points) and favorable gut microbiota changes.
Confidence Level
Low: small sample (n=10), no control group, no blinding, short follow-up (1 month), and patients had concurrent CDI treatment.
Study Flags
Red Flags
- •No control group (uncontrolled case series)
- •Very small sample size (n=10)
- •Short follow-up (1 month) and potential confounding from CDI treatment
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Cognitive improvement of 6 points on MMSE in just one month after FMT
Typical dementia progression is slow decline; an improvement of this magnitude is rarely seen with existing treatments, especially in severe dementia (baseline MMSE 10).
Practical Takeaways
Focus on gut health through diet, probiotics, and avoiding unnecessary antibiotics to maintain a diverse microbiome.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like watching a few people who got a special treatment and then seemed to get better. But without comparing them to people who didn't get the treatment, we can't know if the treatment actually helped or if they just got better on their own. So we can say 'these people got better after the treatment' but we can't say 'the treatment caused them to get better.'
Strengths
- Prospective data collection with pre- and post-intervention assessments
- Use of validated cognitive tests (MMSE, CDR-SB)
- Microbiota analysis adds descriptive depth
Weaknesses
- No control group
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Scientists gave 10 older people with memory loss and a bad gut infection a fecal transplant (putting healthy poop into their gut). One month later, their memory and thinking tests improved a lot.
Research results
Before treatment, average memory test score was 10/30; after, it was 16/30. Another test of dementia severity improved from 10 to 5.5 (lower is better).
What this means - more context
This is a big improvement—like going from needing a lot of help to needing less help—but the study is too small and lacks a comparison group to be sure the transplant caused it.
To evaluate whether fecal microbiota transplantation (FMT) can improve cognition in patients with dementia and Clostridioides difficile infection (CDI).
In a case series of 10 dementia patients with severe CDI, FMT was associated with improved cognitive function (MMSE increased from median 10 to 16; CDR-SB decreased from median 10 to 5.5) and shifts in gut microbiota (increased Bacteroidetes, decreased Proteobacteria) one month post-treatment.
Methods Used
10 patients (63-90 years, 80% female) with dementia and severe CDI underwent FMT; cognitive tests (MMSE, CDR-SB) were performed one month before and after FMT; stool samples analyzed by PCR before and 3 weeks after FMT.
Main Finding
FMT in dementia patients with CDI led to significant cognitive improvement (median MMSE +6 points, median CDR-SB -4.5 points) and favorable gut microbiota changes.
Confidence Level
Low: small sample (n=10), no control group, no blinding, short follow-up (1 month), and patients had concurrent CDI treatment.
Study Flags
Red Flags
- •No control group (uncontrolled case series)
- •Very small sample size (n=10)
- •Short follow-up (1 month) and potential confounding from CDI treatment
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Cognitive improvement of 6 points on MMSE in just one month after FMT
Typical dementia progression is slow decline; an improvement of this magnitude is rarely seen with existing treatments, especially in severe dementia (baseline MMSE 10).
Practical Takeaways
Focus on gut health through diet, probiotics, and avoiding unnecessary antibiotics to maintain a diverse microbiome.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
Human Case Report
Subject
Lower probability
on the GRADE evidence scale
This study is like watching a few people who got a special treatment and then seemed to get better. But without comparing them to people who didn't get the treatment, we can't know if the treatment actually helped or if they just got better on their own. So we can say 'these people got better after the treatment' but we can't say 'the treatment caused them to get better.'
Strengths
- Prospective data collection with pre- and post-intervention assessments
- Use of validated cognitive tests (MMSE, CDR-SB)
- Microbiota analysis adds descriptive depth
Weaknesses
- No control group
- No randomization
- No blinding
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
This study is like a small experiment where everyone got the same thing and no one was in a 'pretend' group. That makes it hard to trust the results because we don't know if the improvement would have happened anyway. A better study would have a comparison group and use random chance to decide who gets the treatment, so we can be more sure the treatment is what really made a difference.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
14 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=10)+1.0/20
- Follow-up+10/10
100 / 100
23 / 100
- P-values+15/15
- Effect sizeno effect size reported
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 530 / 100
Probability of being correct
Snapshots of a population at a single point in time, or descriptions of small groups. Can identify correlations and prevalence, but cannot determine cause and effect.
This design cannot establish causation — the findings describe an association, not a cause. This is a case series with no control group, no randomization, and no blinding. Therefore, it cannot establish cause-effect relationships. Any observed improvements could be due to natural history, placebo effects, or confounding factors.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding information disclosed in the provided abstract.
The study appears to be conducted by academic researchers, but the full article may contain COI and funding statements not included here.